洪韬

洪韬课题组面向脑出血疾病防治的重大国家需求，实践多学科交叉、临床和基础研究结合的创新研究路径，致力于推动中国此类疾病的防治达到世界先进水平。

洪韬课题组致力于脑出血疾病的机制和防治策略研究。在既往的工作中，聚焦脑出血疾病的遗传机制解析、相关基础研究平台的发展和创新疗法的研发。研发血管畸形复合手术策略，发现血管畸形体细胞突变核心遗传机制，建立疾病动物模型、揭示致病关键通路和潜在的药物治疗靶点，推动血管畸形未来手术药物联合精准治疗体系的发展。近年来洪韬教授以第一或通讯作者在Brain、JAMA Neurology、Exp Mol Med、Angiogenesis、American Journal of Human Genetics等高影响力学术期刊发表22篇研究性论文。

团队依托国家神经疾病医学中心的优势平台，拥有独立的实验空间和充裕的科研经费，组建了一支优秀的科研团队、形成了临床医生和科学家相互融合的良好氛围。团队与北京大学生物医学前沿创新中心、北京脑科学和类脑研究中心、北京生命科学研究所等多个知名科研团队携手，具有卓越的多学科和多机构协作能力。

团队主要团队主要研究方向包括：

1. 基于临床队列和生物样本的脑出血疾病风险分层预警和早期阻断策略研究；

2. 基于动物模型和多组学技术的脑出血疾病致病机制研究和药物治疗策略开发；

3. 脑出血疾病新诊疗策略的临床研究。

荣誉及奖励：

1) 2024.08，国家杰出青年科学基金获得者

2) 2023.05，北京青年五四奖章

3) 2021.08，国家自然科学基金优秀青年基金获得者

4) 2020.07，北京市百千万人才工程

学术兼职：

1) 2025.02-至今，Journal of NeuroInterventional Surgery（JNIS）编委

2) 2025.02-2028.02，中国医师协会神经介入专业委员会常务委员兼总干事

3) 2024.01-2026.12，Fundamental Research期刊第一届青年编委

4) 2017年-至今，中国脑脊髓血管畸形大会秘书长

5) 2024.05-2029.05，北京医师协会神经介入专科医师分会，副会长

6) 2022.09-2026.09，中国神经科学学会神经外科基础与临床分会，委员

7) 2021.01-2023.12，国家卫健委能力建设和继续教育神经外科学专委会，秘书长

8) 2019.06-2023.06，中国卒中学会神经介入分会青委会，副主任委员

9) 2018.09-2023.09，中华医学会神经外科学分会，青年委员

1) Hong T#, Yan Y#, Li J#, Radovanovic I, Ma X, Shao YW, Yu J, Ma Y, Zhang P, Ling F, Huang S, Zhang H* and Wang Y*. High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. Brain. 2019;142:23-34.

2) Hong T#, Xiao X#, Ren J#, Cui B, Zong Y, Zou J, Kou Z, Jiang N, Meng G, Zeng G, Shan Y, Wu H, Chen Z, Liang J, Xiao X, Tang J, Wei Y, Ye M, Sun L, Li G, Hu P, Hui R, Zhang H* and Wang Y*. Somatic MAP3K3 and PIK3CA mutations in sporadic cerebral and spinal cord cavernous malformations. Brain. 2021;144:2648-2658.

3) Yu JX#, He C#, Ye M#, Li GL, Bian LS, Yang F, Zhai XD, Ling F, Zhang HQ* and Hong T*. The efficacy and deficiency of contemporary treatment for spinal cord arteriovenous shunts. Brain. 2021;144:3381-3391.

4) Yu JX#, Hong T#, Krings T, He C, Ye M, Sun LY, Zhai XD, Xiang SS, Ma YJ, Bian LS, Ren J, Tao PY, Li JW, Yang F, Li GL, Ling F and Zhang HQ*. Natural history of spinal cord arteriovenous shunts: an observational study. Brain. 2019;142:2265-2275.

5) Ren J#, Huang Y#, Ren Y#, Tu T, Qiu B, Ai D, Bi Z, Bai X, Li F, Li JL, Chen XJ, Feng Z, Guo Z, Lei J, Tian A, Cui Z, Lindner V, Adams RH, Wang Y, Zhao F, Körbelin J, Sun W, Wang Y, Zhang H, Hong T* and Ge WP*. Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations. Brain. 2023;146:3634-3647.

6) Ren J#, Cui Z#, Jiang C#, Wang L, Guan Y, Ren Y, Zhang S, Tu T, Yu J, Li Y, Duan W, Guan J, Wang K, Zhang H, Xing D, Kahn ML, Zhang H* and Hong T*. GNA14 and GNAQ somatic mutations cause spinal and intracranial extra-axial cavernous hemangiomas. Am J Hum Genet. 2024;111:1370-1382.

7) Tu T, Zhang S, Li J, Jiang C, Ren J, Zhang S, Meng X, Peng H, Xing D, Zhang H*, Hong T* and Yu J*. Inhibition of Angiopoietin-2 rescues sporadic brain arteriovenous malformations by reducing pericyte loss. Angiogenesis. 2024;28:1-15.

8) Tu T#, Yu J#, Jiang C#, Zhang S, Li J, Ren J, Zhang S, Zhou Y, Cui Z, Lu H, Meng X, Wang Z, Xing D, Zhang H* and Hong T*. Somatic Braf(V600E) mutation in the cerebral endothelium induces brain arteriovenous malformations. Angiogenesis. 2024;27:441-460.

9) Ren J#, Xiao X#, Li R#, Lv C, Zhang Y, Wang L, Hong T*, Zhang H* and Wang Y*. Single-cell sequencing reveals that endothelial cells, EndMT cells and mural cells contribute to the pathogenesis of cavernous malformations. Exp Mol Med. 2023;55:628-642.

10) Ren J, Wei Y and Hong T*. Combined Cranial Intraosseous and Cerebral Cavernous Malformations With Pathogenic CCM1 Germline Sequence Variations. JAMA Neurol. 2021;78:247-248.

11) Lu HH#, Li ZS#, Li JW, Li GL, He C, Ye M, Hu P, Sun LY, Ma YJ, Ren J, Ling F, Zhang HQ, Yu JX and Hong T*. The natural course, treatment outcomes, and long-term prognosis of cervical spinal cord arteriovenous shunts. J Neurosurg. 2024;141:1212-1224.

12) Yu J#, Zhang S#, Bian L#, He C, Ye M, Li G, Hu P, Sun L, Ling F, Zhang H* and Hong T*. Clinical features and outcomes of perimedullary arteriovenous fistulas: comparison between micro- and macro-type lesions. J Neurointerv Surg. 2023;15:821-827.

13) Ren J#, Jiang N#, Bian L#, Dmytriw AA, Zeng G, He C, Sun L, Li X, Ma Y, Yu J, Li G, Ye M, Hu P, Li J, Yang F, Li Q, Ling F, Zhang H* and Hong T*. Natural History of Spinal Cord Cavernous Malformations: A Multicenter Cohort Study. Neurosurgery. 2022;90:390-398.

14) Feng Y#, Yu J#, Xu J#, He C, Bian L, Li G, Ye M, Hu P, Sun L, Jiang N, Ling F, Hong T* and Zhang H*. Natural History and Clinical Outcomes of Paravertebral Arteriovenous Shunts. Stroke. 2021;52:3873-3882.

15) Ren J#, Wang D#, Wang L, Jiang C, Tian A, Cui Z, Ren Y, Bian L, Zeng G, Meng G, Shan Y, Liang J, Xiao X, Tang J, Wei Y, He C, Sun L, Ma Y, Yu J, Li G, Ye M, Hu P, Li J, Li Y, Niu L, Li Q, Ling F, Burkhardt JK, Zhang H* and Hong T*. Clinical, genomic, and histopathologic diversity in cerebral cavernous malformations. Acta Neuropathol Commun. 2025;13:23.

16) Ren J#, Hong T#, Zeng G, He C, Li X, Ma Y, Yu J, Ling F and Zhang H*. Characteristics and Long-Term Outcome of 20 Children With Intramedullary Spinal Cord Cavernous Malformations. Neurosurgery. 2020;86:817-824.

17) He Y#, Hong T#, Wang M#, Jiao L#, Ge Y, Haacke EM, Li T* and Hongqi Z*. Prevention and control of COVID-19 in neurointerventional surgery: expert consensus from the Chinese Federation of Interventional and Therapeutic Neuroradiology (CFITN) and the International Society for Neurovascular Disease (ISNVD). J Neurointerv Surg. 2020;12:658-663.

18) Ren J#, Hong T#, He C, Li X, Ma Y, Yu J, Ling F and Zhang H*. Surgical approaches and long-term outcomes of intramedullary spinal cord cavernous malformations: a single-center consecutive series of 219 patients. J Neurosurg Spine. 2019;31:123-132.

19) Hong T, Park JE, Ling F, terBrugge KG, Tymianski M, Zhang HQ* and Krings T*. Comparison of 3 Different Types of Spinal Arteriovenous Shunts below the Conus in Clinical Presentation, Radiologic Findings, and Outcomes. AJNR Am J Neuroradiol. 2017;38:403-409.